Longbio Pharma (Suzhou) Co Ltd
01779
Company Profile
Business description
Longbio Pharma (Suzhou) Co Ltd is a clinical-stage biotechnology company. The company and its subsidiaries are principally engaged in the research, development, manufacture and commercialisation of pharmaceutical products in the People's Republic of China (the PRC). It has developed a comprehensive product pipeline for biologic treatments targeting rhinology, dermatology, respiratory, hematology, nephrology and other autoimmune diseases, targeting allergic and autoimmune diseases. Its pipeline includes LP-003, LP-00A, LP-005, LP-00C, and LP-00D.
Contact
No. 128 Yinhe Road, Dongnan Subdistrict
5th Floor, Building F, Area A
Changshu City, Jiangsu Province
Suzhou
CHNT: +86 2158372970
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
85
Stocks News & Analysis
stocks
Is SpaceX a threat to this ASX giant?
Investors are raising concerns about the future of telecommunication connectivity in Australia.
stocks
Chart of the Week: This ASX top pick might be overlooked
ASX top pick remains cheap as investor concerns around wage costs might be overdone.
stocks
ASX share undervalued as margins expected to rebound
This ASX share remains overlooked despite a strong outlook.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,165.90 | 50.20 | 0.55% |
| CAC 40 | 8,430.79 | 16.48 | -0.20% |
| DAX 40 | 24,934.67 | 24.26 | 0.10% |
| Dow JONES (US) | 51,492.55 | 507.12 | -0.98% |
| FTSE 100 | 10,508.61 | 14.40 | 0.14% |
| HKSE | 24,312.16 | 181.79 | -0.74% |
| NASDAQ | 26,021.66 | 354.69 | -1.34% |
| Nikkei 225 | 70,535.18 | 632.93 | 0.91% |
| NZX 50 Index | 13,366.84 | 26.14 | -0.20% |
| S&P 500 | 7,420.10 | 91.25 | -1.21% |
| S&P/ASX 200 | 8,948.70 | 47.90 | 0.54% |
| SSE Composite Index | 4,108.08 | 16.18 | 0.40% |